252 related articles for article (PubMed ID: 30993902)
21. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
22. Screening for cancer in low- and middle-income countries.
Sankaranarayanan R
Ann Glob Health; 2014; 80(5):412-7. PubMed ID: 25512156
[TBL] [Abstract][Full Text] [Related]
23. Education, income and occupation and their influence on the uptake of cervical cancer prevention strategies: A systematic review.
Murfin J; Irvine F; Meechan-Rogers R; Swift A
J Clin Nurs; 2020 Feb; 29(3-4):393-415. PubMed ID: 31713934
[TBL] [Abstract][Full Text] [Related]
24. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.
Hall MT; Simms KT; Lew JB; Smith MA; Saville M; Canfell K
PLoS One; 2018; 13(2):e0185332. PubMed ID: 29444073
[TBL] [Abstract][Full Text] [Related]
25. Mapping HPV Vaccination and Cervical Cancer Screening Practice in the Pacific Region-Strengthening National and Regional Cervical Cancer Prevention.
Obel J; McKenzie J; Buenconsejo-Lum LE; Durand AM; Ekeroma A; Souares Y; Hoy D; Baravilala W; Garland SM; Kjaer SK; Roth A
Asian Pac J Cancer Prev; 2015; 16(8):3435-42. PubMed ID: 25921158
[TBL] [Abstract][Full Text] [Related]
26. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
[TBL] [Abstract][Full Text] [Related]
27. On surmounting the barriers to HPV vaccination: we can do better.
Attia AC; Wolf J; Núñez AE
Ann Med; 2018 May; 50(3):209-225. PubMed ID: 29316825
[TBL] [Abstract][Full Text] [Related]
28. Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach.
Setiawan D; Kotsopoulos N; Wilschut JC; Postma MJ; Connolly MP
PLoS One; 2016; 11(8):e0160707. PubMed ID: 27490258
[TBL] [Abstract][Full Text] [Related]
29. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
Borracci RA; Segal SV; Méndez JH
Medicina (B Aires); 2018; 78(5):315-328. PubMed ID: 30285924
[TBL] [Abstract][Full Text] [Related]
30. Community-based household assessment of human papillomavirus (HPV) vaccination coverage and acceptability - HPV vaccine demonstration program, Cambodia - 2017.
Garon J; Wuddhika IV; Sreenivasan N; Wannemuehler K; Vutthikol Y; Chhorvann C; Loharikar A
Vaccine; 2019 Feb; 37(9):1202-1208. PubMed ID: 30686637
[TBL] [Abstract][Full Text] [Related]
31. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
[TBL] [Abstract][Full Text] [Related]
32. An overview on the implementation of HPV vaccination in Europe.
Bonanni P; Levi M; Latham NB; Bechini A; Tiscione E; Lai P; Panatto D; Gasparini R; Boccalini S
Hum Vaccin; 2011; 7 Suppl():128-35. PubMed ID: 21245659
[TBL] [Abstract][Full Text] [Related]
33. Integrating HPV vaccination programs with enhanced cervical cancer screening and treatment, a systematic review.
Wirtz C; Mohamed Y; Engel D; Sidibe A; Holloway M; Bloem P; Kumar S; Brotherton J; Reis V; Morgan C
Vaccine; 2022 Mar; 40 Suppl 1():A116-A123. PubMed ID: 34863615
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology and cost of cervical cancer care and prevention in Apulia (Italy), 2007/2016.
Bianchi FP; Gallone MS; Fortunato F; Boccalini S; Martinelli D; Prato R; Tafuri S
Ann Ig; 2018; 30(6):490-501. PubMed ID: 30614498
[TBL] [Abstract][Full Text] [Related]
35. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
Moss JL; Reiter PL; Brewer NT
Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
[TBL] [Abstract][Full Text] [Related]
36. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
Martín-Merino E; Llorente-García A; Castillo Cano B; Montero Corominas D; Huerta-Álvarez C
Pharmaceut Med; 2019 Dec; 33(6):519-530. PubMed ID: 31933243
[TBL] [Abstract][Full Text] [Related]
37. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
38. [Prevention of cervical cancer (II): prophylactic HPV vaccination, current knowledge, practical procedures and new issues].
Monsonego J
Presse Med; 2007 Apr; 36(4 Pt 2):640-66. PubMed ID: 17350792
[TBL] [Abstract][Full Text] [Related]
39. Cervical screening in HPV-vaccinated populations.
Canfell K
Climacteric; 2018 Jun; 21(3):227-234. PubMed ID: 29565690
[TBL] [Abstract][Full Text] [Related]
40. Cervical Cancer Prevention in Rural Areas.
Zhetpisbayeva I; Kassymbekova F; Sarmuldayeva S; Semenova Y; Glushkova N
Ann Glob Health; 2023; 89(1):75. PubMed ID: 37928103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
